IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

PUSCEDDU, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.578
NA - Nord America 2.048
AS - Asia 1.854
SA - Sud America 160
AF - Africa 40
OC - Oceania 6
Totale 6.686
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.993
DE - Germania 1.244
CN - Cina 614
SG - Singapore 563
GB - Regno Unito 429
IT - Italia 249
SE - Svezia 170
BD - Bangladesh 160
HK - Hong Kong 153
VN - Vietnam 144
RU - Federazione Russa 129
BR - Brasile 121
FR - Francia 83
IN - India 65
NL - Olanda 62
FI - Finlandia 59
IE - Irlanda 57
CA - Canada 43
ID - Indonesia 30
KR - Corea 25
UA - Ucraina 25
CI - Costa d'Avorio 21
DK - Danimarca 20
AR - Argentina 14
TR - Turchia 14
PL - Polonia 13
JP - Giappone 12
PK - Pakistan 12
BE - Belgio 11
IQ - Iraq 11
CO - Colombia 9
PH - Filippine 9
MX - Messico 8
UZ - Uzbekistan 6
ZA - Sudafrica 6
ES - Italia 5
MY - Malesia 5
AU - Australia 4
CH - Svizzera 4
PE - Perù 4
PT - Portogallo 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
AZ - Azerbaigian 3
JM - Giamaica 3
JO - Giordania 3
NP - Nepal 3
PY - Paraguay 3
SA - Arabia Saudita 3
TW - Taiwan 3
BO - Bolivia 2
EC - Ecuador 2
KE - Kenya 2
KW - Kuwait 2
MA - Marocco 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AO - Angola 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
EG - Egitto 1
ET - Etiopia 1
GA - Gabon 1
GF - Guiana Francese 1
GR - Grecia 1
IM - Isola di Man 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
MV - Maldive 1
RS - Serbia 1
TG - Togo 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UG - Uganda 1
ZW - Zimbabwe 1
Totale 6.686
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 1.136
Southend 384
Singapore 321
Ashburn 268
Chandler 236
San Jose 139
Hong Kong 128
Dallas 116
Milan 100
Fairfield 94
Beijing 72
Seattle 68
Council Bluffs 64
Princeton 64
Dearborn 61
Wilmington 58
Dublin 57
Houston 52
Ho Chi Minh City 50
New York 50
Munich 47
Woodbridge 42
Hanoi 40
Ann Arbor 35
Lauterbourg 35
Los Angeles 35
Nanjing 33
Jinan 32
Buffalo 31
Santa Clara 31
Cambridge 29
Moscow 29
Bengaluru 28
Boardman 28
Hefei 28
Helsinki 28
Guangzhou 27
Des Moines 26
Shenyang 26
Changsha 24
Jakarta 23
Abidjan 21
Columbus 19
The Dalles 17
Hebei 16
Cangzhou 15
Toronto 15
Seoul 14
Shanghai 14
Turku 14
Phoenix 13
Fuzhou 12
Zhengzhou 12
Brussels 11
Da Nang 11
London 9
Montreal 9
Tokyo 9
Warsaw 9
Wuhan 9
Hangzhou 8
Mumbai 8
Shenzhen 8
São Paulo 8
Tianjin 8
Baghdad 7
Chengdu 7
Fremont 7
Haikou 7
Islamabad 7
Naples 7
Ottawa 7
Redwood City 7
Rio de Janeiro 7
Atlanta 6
Central District 6
Chicago 6
Eitensheim 6
Jiaxing 6
Nanchang 6
Nuremberg 6
Rome 6
Andover 5
Berlin 5
Erlangen 5
Kent 5
Kunming 5
Madignano 5
San Diego 5
Tashkent 5
Turin 5
Bexley 4
Brasília 4
Bühl 4
Bắc Ninh 4
Istanbul 4
Johannesburg 4
Silver Spring 4
Alexandria 3
Amman 3
Totale 4.654
Salva come PNG Salva come JPEG
Nome #
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis 320
Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs) 307
Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis 280
Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives 252
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up 247
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. 246
Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms 245
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies 243
Diagnosis and management of typical and atypical lung carcinoids 228
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers 227
Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum 217
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy : a phase II ITMO study 208
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors 205
Safety profile and treatment response of everolimus in different solid tumors : an observational study 205
Update on medical treatment of small intestinal neuroendocrine tumors 204
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes 196
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer 195
Erratum: Real-world study of everolimus in advanced progressive neuroendocrine tumors (The Oncologist, (2014) 19, (966-974), 10.1634/theoncologist.2014-0037) 194
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors 192
Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs 192
From biology to clinical experience : evolution in the knowledge of neuroendocrine tumours 188
Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver 182
Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors 180
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 169
Well-differentiated neuroendocrine tumor of tailgut cyst : A rare entity with controversial medical opportunities 157
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 155
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2 149
Pancreatic well-differentiated neuroendocrine neoplasms (PWDNENS) : What place for everolimus and sunitinib derived from esmo clinical practice guidelines in the therapeutic algorithm? 149
Malignant pheochromocytoma and paraganglioma : future considerations for therapy 146
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors 128
Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites : Grade, mesenteric tumour deposits and emerging novelties 119
Treatment of lung large cell neuroendocrine carcinoma 115
Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options : a systematic review 113
The underestimated role of somatostatin analogs in the NETTER-1 trial 101
The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence 85
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential 76
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 74
Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors 65
null 1
Totale 6.955
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.035
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.035
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 0 0 0 0 0 0 23
2021/2022335 19 11 14 17 17 15 26 15 22 65 13 101
2022/2023596 71 85 51 73 51 112 9 32 53 11 40 8
2023/2024997 6 21 21 10 70 21 171 144 72 143 156 162
2024/20251.285 148 169 123 154 60 34 38 83 49 117 79 231
2025/20262.208 224 174 207 161 241 120 276 83 213 146 302 61
Totale 6.955